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Purpose
Multidrug-resistant Acinetobacter Baumannii (MDRAB)
is a worldwide threat because of its remarkable ability to
survive in harsh environment for months. It has been
shown that MDRAB can colonize patient environment
[1], especially in intensive care units (ICU). This study
aims to compare the prevalence and antimicrobial sus-
ceptibility pattern of Acinetobacter Baumannii infecting
ICU patients before and after relocation.
Methods
A retrospective study including all patients with Acineto-
bacter Baumannii (AB) infections, admitted in ICU
between January 2013 and January 2015; the relocation
occurred in September 2013. We recorded the site of
infection, the antimicrobial susceptibility, antibiotic ther-
apy and the outcome.
Results
310 patients were hospitalized in intensive care unit:
160 in the old location and 150 in the new one.
Among the 310 patients, 36 developed infection with
AB isolated in 45 cultures: 17 in the old location and
19 in the new one. In the old location, isolates were
resistant to imipenem in 66%, 100% to amikacin, 100%
to quinolones, and 16% susceptible to fosfomycin,
94.11% susceptible to colistin, 94% to rifampicin and
100% to tigecycline, however in the new location, we
noted 95% resistance to imipenem, 21% resistance to
amikacin, 100% resistance to quinolones, and 20% sus-
ceptibility to fosfomycin, 100% to colistin, 94.7% to
rifampicin and 100% susceptible to tigecycline. All
patients have received a combination therapy adapted
to microbiological findings: 2.7% Fosfomycin + colistin,
13.8% imipenem + colistin, 38.8% colistin + Rifampicin,
44.7% Tigecycline + colistin. The mortality rate was
72.3%: 74% related to refractory septic shock and 26%
due to different causes.
Discussion
The main risk factors for nosocomial infections in
ICUs are: assisted ventilation, large prescription of
antibiotics, prolonged hospital stay and catheterization.
Stringent measures had to be applied: restricted policy
for the use of specific drugs, septic isolation, disinfec-
tion of the environment and even the closure of the
unit. Furthermore, the resistance of the AB affects dif-
ferent classes of antibiotics such as carbapenems. How-
ever, resistance to imipenem is variable according to
the authors, ranging from 3.1 to 60% [2]. No resistance
of AB to colistin was found according to various stu-
dies [3]. For multidrug-resistant AB, the antibiotherapy
with colistin, rifampicin and tigecycline [4] have been
associated with” favorable” clinical outcomes.
Conclusions
The spread of multidrug-resistant AB in ICU presents a
challenge to clinician. It is necessary to intensify efforts
to respect hygiene rules and restriction in the use of
antibiotics.
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